Erratum: Expression of urokinase-type plasminogen activator and its receptor in gastric fibroblasts and effects of nonsteroidal antiinflammatory drugs and prostaglandin (Digestive Diseases and Sciences (2003) 48:12 (2247-2256) DOI: 10.1023/B:DDAS.0000007859.10680.b1);Expression of Urokinase-Type Plasminogen Activator and Its Receptor in Gastric Fibroblasts and Effects of Nonsteroidal Antiinflammatory Drugs and Prostaglandin

Digestive Diseases and Sciences

Volumn 48, Issue 12, 2003, Pages 2247-2256

  Iwamoto, Jun Ichi ^a   Takahashi, Kimiko ^a   Mizokami, Yuji ^a   Otsubo, Toshiya ^a   Miura, Syuuhei ^a   Narasaka, Toshiaki ^a   Takeyama, Hiroki ^a   Omata, Takayuki ^a   Shimokoube, Kouichi ^a   Matsuoka, Takeshi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Gastric fibroblasts; Nonsteroidal antiinflammatory drugs; uPA receptor; Urokinase type plasmonigen activator

Indexed keywords

INDOMETACIN; INTERLEUKIN 1BETA; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; FIBROBLAST; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; STOMACH MUCOSA; STOMACH ULCER; TISSUE INJURY; TISSUE REGENERATION; TISSUE REPAIR; WOUND HEALING;

EID: 9144235449     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-2005-3     Document Type: Erratum

References (32)

1. Reilly D, Andreasen PA, Duffy MJ: Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay. Blood Coagul Fibrinolysis 2:47-50, 1991
2. Miseljic S, Galandiuk S, Myers SD, Wittliff JL: Expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in colon disease. J Clin Lab Anal 9:413-417, 1995
3. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, Schildberg FW: The prognostic impact of the urokinase-type plasminogen activator system is associated with tumor differentiated in gastric cancer. Eur J Surg Oncol 22:74-7, 1996
4. Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS: High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer 79:878-83, 1997
5. De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S: Expression of urokinase-type plasminogen activator, u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res 58:2234-2239, 1998
6. Herszènyi L, Plebani M, Carrao P, De Paoli M, Cardin R, Di Mario F, Kusstatscher S, Naccarato R, Farinati F: Impaired fibrinolysis and increased pretease levels in gastric and duodenal mucosa of patients with active duodenal ulcer. Am J Gastroenterol 92:843-847, 1997
7. Wodziński MA, Bardhan KD, Reilly JT, Cooper P, Preston FE: Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease. Gut 34:1310-1314, 1993
8. Takahashi K, Uwabe Y, Sawasaki Y, Kiguchi T, Nakamura H, Kashiwabara K, Yagyu H, Matsuoka T: Increased secretion of urokinase-type plasminogen activator by human lung microvascular endothelial cells. Am J Physiol 275:47-54, 1998
9. Vassalli JD, Sappino A, Belin D: The plasmonigen a activator/plasmin system. J Clin Invest 88:1067-1072, 1991
10. Dano K, Andreasen PA, Gronbahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266, 1985
11. Blasi F, Vassalli J, Dano K: Urokinase-type plasminogen activator, proenzyme, recepter, and inhibitors. J Cell Biol 104:801-804, 1987
12. Nishino N, Aoki K, Tokura Y, Sakaguchi S, Takada Y, Takada A: The urokinase type of plasminogen activator in cancer of digestive tracts. Thromb Res 50:527-535, 1988
13. Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, Comoglio PM: Biological activation of pro-HGF by urokinase is controlled by a stoichiometric reaction. J Biolog Chem 270:603-611, 1995
14. Naldini L, Tamagnone L, Vigna E, Sschs M, Hartmann G, Birchmeier W: Extracallular proteolytic cleavage by uroknase is required for activation of hepatocyte growth factor. EMBO J 11:4825-4833, 1992
15. Okusa Y, Ichikura T, Mochizuki H, Shinomiya N: Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines. Int J Oncol 17:1001-1005, 2000
16. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S: Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41:4629-4636, 1981
17. Jones PA, De Clerck YA: Extracellular matrix destruction by invasive tumor cells. Cancer Metastasis Rev 1:289-317, 1982
18. Takahashi M, Ota S, Hata Y, Mikima Y, Azuma N, Nakamura T, Terano A: Hepatocyte growth factor as a key to modulate anti-ulcer action of prostaglandins in stomach. J Clin Invest 98:2604-2611, 1996
19. Takahashi M, Katayama Y, Takada H, Kuwayama H, Terano A: The effect of NSAIDs and a cox-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGFin human gastric fibroblasts. Aliment Pharmacol Ther 14 (Suppl 1):44-49, 2000
20. Bamba H, Ota S, Kato A, Matsuzaki F: Nonsteroidal antiinflammatory drugs may delay the repair of gastric mucosa by suppressing prostaglandin-mediated increase of hepatocyte growth factor production. Biochem Biophys Res Commun 245:567-571, 1998
21. Quax PHA, van den Hoogen CM, Verheijen JH, Padro T, Zeheb R, GelehrterTD, van Barkel TJC, Kuiper J, Emeis JJ: Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissue in vivo. J Biol Chem 15:15560-15563, 1990
22. Niedbala MJ, Stein M: Tumor necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells. Biomed Biochim Acta 50:427-436, 1991
23. Mignatti P, Rifkin DB: Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49:117-137, 1996
24. Sun DCH, Roth SH, Mitchell CS: Upper gastrointestinal disease in rheumatoid arthritis. Dig Dis Sci 19:405-410, 1974
25. Hawkey CJ, Hudson N: Mucosal injury caused by drugs, chemicals, and stress. In Bockus Gastroenterology, 5th ed, vol. 1995, pp 656-699, Saunders, Philadelphia.
26. Larkai EN, Lacey Smith J, Lidsky MD: Gastroduodenal mucosa and dtspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 82:1153-1158, 1987
27. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 231:232-235, 1971
28. Kobayashi K, Arakawa T, Satoh H, et al: Effect of indomethacin, tiaprofenic acid, and dicrofenic acid, and dicrofenac on rat gastric mucosal damage and content of prostacyclin and prostaglandin E2. Prostaglandins 30:609-618, 1985
29. Robert A: Cytoprotection by prostaglandins. Gastroenterology 77:761-767, 1979
30. Gretzer B, Ehrlich K, Maricic N: Selective cyclooxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rar stomach. Br J Pharmacol 123:927-935, 1998
31. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T, Kasuga M: Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112:387-397, 1997
32. Tatsuguchi A, Sakamoto C, Wada K, Akamatsu T, Tsukui T, Miyake K, Futagami S: Localisation of cyclooygenase 1 and 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut 2000:782-789, 2000